Non-opioid Pain Treatment Market Growth Trends, Revenue, Challenges and Future Outlook
Non-opioid Pain Treatment Market Growth, Size, Trends Analysis - By Drug Class, By Pain, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Mar-2025 | Report ID: HLCA2578 | Pages: 1 - 220 | Formats*: |
| Category : Healthcare | |||
Non-opioid Pain Treatment Market Introduction and Overview
According to SPER Market Research, the Global Non-opioid Pain Treatment Market is estimated to reach USD 104.89 billion by 2034 with a CAGR of 7.53%.
The report includes an in-depth analysis of the Global Non-opioid Pain Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The Non-opioid Pain Treatment Market was valued at USD 50.75 billion in 2024 and is expected to grow at a rate of 7.53% from 2025 to 2034. This growth is due to the rising number of chronic pain conditions and concerns about opioid addiction. With more people suffering from arthritis, back pain, and neuropathic disorders, there is a greater demand for effective pain management drugs. As patients look for safer alternatives to opioids, the market for non-opioid treatments like NSAIDs and analgesics is expanding.
By Drug Class Insights: The Non-steroidal Anti-Inflammatory Drugs (NSAIDs) segment led the market in 2024 due to high prescription rates and easy global access. Their popularity highlights NSAIDs as a key choice for pain management, minimizing opioid use and the related risks of addiction and overdose. Their availability and effectiveness are crucial for safer pain treatment options.
By Route of Administration Insights: Oral segment dominated the market with a significant revenue share in 2024. The approval and introduction of new oral NSAIDs have greatly improved pain management options. Common oral non-opioid analgesics include Celebrex, Dyloject, Zipsor, and Zorvolex, as well as Anaprox, Ec-Naprosyn, Treximet, and Naprelan. Other notable medications include Nalfon, Advil, Motrin, Lodine, and Daypro. These medications provide effective, non-opioid alternatives for managing cramps.
By Distribution Channel Insights: The retail pharmacies segment led the market with a large revenue share in 2024 and is projected to grow the fastest during the forecast period. This growth is due to the wide availability and easy access to non-opioid analgesics for patients. Key providers include CVS Health, Walgreens Boots Alliance, Ahold Delhaize, Albertsons Companies, and Rite Aid.
Regional Insights: North America has dominated the non-opioid pain treatment market, owing to its emphasis on alternative pain management techniques. The North American market has been driven by high healthcare costs, as well as extensive availability and adoption of novel treatment choices. The presence of significant players, as well as the availability of new technologies, provide patients with simple access to novel treatment options. Furthermore, the expanding senior population, which is prone to chronic pain, contributes to regional growth.
Market Competitive Landscape:
The industry is characterised by fierce competition among pharmaceutical companies, driven by rising demand for safer, non-addictive pain management options. Companies are focussing on increasing their pharmaceutical portfolios through novel formulations such as extended-release and combination medicines. Many corporations invest in enhanced medicine delivery technologies and innovative chemicals, emphasising the importance of R&D. industry participants also compete by forming strategic alliances, acquiring companies, and expanding geographically to strengthen their position in this continually changing industry.
Recent Developments:
- In March 2024, Endo International plc said its subsidiary, Par Pharmaceutical, Inc, launched ibuprofen-famotidine 800 mg/26. 6 mg tablets, a generic version of Amgens DUEXIS. This medication treats rheumatoid arthritis and osteoarthritis while reducing the risk of stomach and intestinal ulcers from ibuprofen.
- Camber Pharmaceuticals plans to commercialise Acetaminophen Injection in July 2024. This medicine is used to treat mild to moderate pain in adults and children aged 2 and up, as well as severe pain with opioids. It also reduces fever in all age groups.
- In April 2024, Vertex Pharmaceuticals created an experimental drug that reduces acute post-surgical pain without addiction risk, highlighting research efforts for non-opioid drugs and business expansion in pain management.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Drug Class, By Pain, By Route of Administration, By Distribution Channel. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Novartis AG, Teva Pharmaceutical Industries Limited, Dr. Reddys Laboratories Ltd, Sun Pharmaceutical Industries Ltd, GSK plc, Pfizer Inc, Perrigo Company plc, LNK International, Inc, Cipla Inc, Johnson & Johnson Services, Inc, Pacira Pharmaceuticals, Inc, Pierrel. and others. |
Key Topics Covered in the Report:
- Global Non-opioid Pain Treatment Market Size (FY’2021-FY’2034)
- Overview of Global Non-opioid Pain Treatment Market
- Segmentation of Global Non-opioid Pain Treatment Market By Drug Class (NSAIDs, Acetaminophen, Local Anesthetics, Other Drug Class)
- Segmentation of Global Non-opioid Pain Treatment Market By Pain (Post-operative Pain, Cancer Pain, Chronic Pain, Other Pain)
- Segmentation of Global Non-opioid Pain Treatment Market By Route of Administration (Oral, Topical, Injectable, Other Route of Administration)
- Segmentation of Global Non-opioid Pain Treatment Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- Statistical Snap of Global Non-opioid Pain Treatment Market
- Expansion Analysis of Global Non-opioid Pain Treatment Market
- Problems and Obstacles in Global Non-opioid Pain Treatment Market
- Competitive Landscape in the Global Non-opioid Pain Treatment Market
- Details on Current Investment in Global Non-opioid Pain Treatment Market
- Competitive Analysis of Global Non-opioid Pain Treatment Market
- Prominent Players in the Global Non-opioid Pain Treatment Market
- SWOT Analysis of Global Non-opioid Pain Treatment Market
- Global Non-opioid Pain Treatment Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Non-opioid Pain Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Non-opioid Pain Treatment Market
7. Global Non-opioid Pain Treatment Market, By Drug Class (USD Million) 2021-2034
7.1. NSAIDs
7.1.1. Non Selective NSAIDs7.1.2. Selective COX-2 Inhibitors
7.2. Acetaminophen7.3. Local Anesthetics7.4. Other Drug Class
8. Global Non-opioid Pain Treatment Market, By Pain (USD Million) 2021-2034
8.1. Post-operative Pain8.2. Cancer Pain8.3. Chronic Pain8.4. Other Pain
9. Global Non-opioid Pain Treatment Market, By Route of Administration (USD Million) 2021-2034
9.1. Oral9.2. Topical9.3. Injectable9.4. Other Route of Administration
10. Global Non-opioid Pain Treatment Market, By Distribution Channel (USD Million) 2021-2034
10.1. Hospital Pharmacies10.2. Retail Pharmacies10.3. Online Pharmacies
11. Global Non-opioid Pain Treatment Market, (USD Million) 2021-2034
11.1. Global Non-opioid Pain Treatment Market Size and Market Share
12. Global Non-opioid Pain Treatment Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia12.1.2. China12.1.3. India12.1.4. Japan12.1.5. South Korea12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France12.2.2. Germany12.2.3. Italy12.2.4. Spain12.2.5. United Kingdom12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia12.3.2. United Arab Emirates12.3.3. Qatar12.3.4. South Africa12.3.5. Egypt12.3.6. Morocco12.3.7. Nigeria12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada12.4.2. Mexico12.4.3. United States
12.5. Latin America
12.5.1. Argentina12.5.2. Brazil12.5.3. Rest of Latin America
13. Company Profile
13.1. Novartis AG
13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments
13.2. Teva Pharmaceutical Industries Limited
13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments
13.3. Dr. Reddys Laboratories Ltd
13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments
13.4. Sun Pharmaceutical Industries Ltd
13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments
13.5. GSK plc
13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments
13.6. Pfizer Inc
13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments
13.7. Perrigo Company plc
13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments
13.8. LNK International, Inc
13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments
13.9. Cipla Inc
13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments
13.10. Johnson & Johnson Services, Inc
13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments
13.11. Pacira Pharmaceuticals, Inc
13.11.1. Company details13.11.2. Financial outlook13.11.3. Product summary13.11.4. Recent developments
13.12. Pierrel
13.12.1. Company details13.12.2. Financial outlook13.12.3. Product summary13.12.4. Recent developments
13.13. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Non-opioid Pain Treatment Market is projected to reach USD 104.89 billion by 2034, growing at a CAGR of 7.53% during the forecast period.
Non-opioid Pain Treatment Market grew in Market size from 2025. The Market is expected to reach USD 104.89 billion by 2034, at a CAGR of 7.53% during the forecast period.
Non-opioid Pain Treatment Market CAGR of 7.53% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Non-opioid Pain Treatment Market size is USD 104.89 billion from 2025 to 2034.
Non-opioid Pain Treatment Market is covered By Drug Class, By Pain, By Route of Administration, By Distribution Channel.
The North America is anticipated to have the highest Market share in the Non-opioid Pain Treatment Market.
The key players in the Market include Companies Covered Novartis AG, Teva Pharmaceutical Industries Limited, Dr. Reddys Laboratories Ltd, Sun Pharmaceutical Industries Ltd, GSK plc, Pfizer Inc, Perrigo Company plc, LNK International, Inc, Cipla Inc, Johnson & Johnson Services, Inc, Pacira Pharmaceuticals, Inc, Pierrel. and others.
This growth is due to the rising number of chronic pain conditions and concerns about opioid addiction. With more people suffering from arthritis, back pain, and neuropathic disorders, there is a greater demand for effective pain management drugs.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
